Tools
Stock profile

Annexon, Inc. (ANNX)

ANNX · Latest close $3.52 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$3.52
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

Annexon, Inc. (ANNX) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($99.8K bought vs $0 sold). Latest close $3.52 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 24, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $99.8K
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Insider trading · 5% holders · Politician trading · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Deerfield Management — 1 tracked fund hold ANNX. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $99.8K) vs 0 sales ($0). Latest buy: Sep 24, 2026. Insider trading

Often held alongside

No closely related stocks by co-holding for this stock. Browse all stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Deerfield Management0.03%583,913HELD Q3 filed Nov 16
Polen Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -37.5% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

6.961.162024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding217 of 8,857 filers
Long-only filers among them216
Change vs 2026 Q1+7 net · 210 entered · 203 exited
Shares reported, all filers178,355,895
Reported value, all filers$1.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Net income · FY2025$-206.7M
Total assets · FY2025$277.6M
Shares outstanding149,362,800
Market cap (at latest close)$525.8M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 202631,627,401
Share of shares outstanding21.17%
Days to cover10.31

Shares short at recent settlements — Jul 31, 2026: 30.8M · Aug 14, 2026: 32.6M · Aug 31, 2026: 32.1M · Sep 15, 2026: 32.9M · Sep 30, 2026: 32.0M · Oct 15, 2026: 31.6M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $99.8K), against 0 sales by 0 insiders ($0). Latest buy: Sep 24, 2026.

CEO/CFO bought

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Love Douglas · 26,065 shares on Sep 24, 2026 · filed Sep 25, 2026$3.83-13.5% (close Sep 28, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Sep 28, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 24, 2026Love DouglasPRESIDENT AND CEOBuy26,065$3.83$99.8KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Nov 21, 2025SCHEDULE 13D/A-23.1% (close Nov 24, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Nov 24, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 7, 2026STATE STREET CORPORATIONSC 13G9,824,3216.0%Jun 30, 2026SEC filing
Jul 27, 2026BlackRock, Inc.SC 13G/A13,128,2818.0%Jun 30, 2026SEC filing
Jul 8, 2026Redmile Group, LLCSC 13G/A17,918,4599.9%Jul 1, 2026SEC filing
Jul 8, 2026FMR LLCSC 13G/A19,518,496.3511.9%Jun 30, 2026SEC filing
May 15, 2026BIOTECHNOLOGY VALUE FUND L PSC 13G/A4,644,8232.9%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026Redmile Group, LLCSC 13G/A15,427,8669.9%Dec 31, 2025SEC filing
Feb 5, 2026FMR LLCSC 13G/A10,222,470.367.1%Dec 31, 2025SEC filing
Jan 21, 2026BlackRock, Inc.SC 13G/A8,868,7556.1%Dec 31, 2025SEC filing
Nov 21, 2025Satter Muneer ASC 13D/A10,444,1347.2%Nov 19, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Government relations

Lobbying: 10 Lobbying Disclosure Act filings named this company as client, 2025–2026; most common issues: Health Issues (5).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· CEO & CFO Buying — Last 90 days: top executives (CEO/CFO) bought on the open market

· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

Key figures

· CEO & CFO Buying — Buy txns: 1 · Buy value: $99.8K · Insiders buying: 1 · Latest buy: Sep 24, 2026

· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $99.8K · Latest buy: Sep 24, 2026

· Distress Risk (Altman Z″) — Z″-Score: -7.93 · Working capital / assets: 0.72 · Retained earnings / assets: -3.31 · EBIT / assets: -0.78 · Equity / liabilities: 3.21

· Excess Accruals (Sloan) — Accruals ratio: -75.8% · Net income: $-206.7M · Operating cash flow: $-186.4M · Investing cash flow: $190.1M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Recent 8-K filings

FiledItemsSource
Nov 9, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 12, 20262.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Aug 10, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Stocks A–Z · Track Record: how the signals scored · Practice timing on ANNX

One email a week: the week’s new filings and research. Subscribe free

← ANL  ·  ANRO →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.